Carter Gould
Stock Analyst at Cantor Fitzgerald
(1.47)
# 1494
Out of 5,328 analysts
222
Total ratings
48.33%
Success rate
5.23%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb | Reiterates: Neutral | 55 55 | 49.77 | 10.51% | 16 | Apr 23, 2025 | |
VRTX Vertex Pharmaceutica... | Assumes: Overweight | 535 | 503.44 | 6.27% | 2 | Apr 22, 2025 | |
REGN Regeneron Pharmaceut... | Assumes: Overweight | 695 | 589.85 | 17.83% | 19 | Apr 22, 2025 | |
PFE Pfizer | Initiates Coverage On: Neutral | 24 | 24.05 | -0.21% | 15 | Apr 22, 2025 | |
PCVX Vaxcyte | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 85 | 84.11 | 1.06% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 975 | 821.57 | 18.68% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 125 | 104.57 | 19.54% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 210 | 194.15 | 8.16% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 160 165 | 108.92 | 51.49% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 20.71 | -3.43% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 190 180 | 123.9 | 45.28% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 286.73 | 9.86% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 77.86 | 28.44% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 0.66 | 354.55% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 1.07 | 180.37% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 1.4 | 542.86% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 43.24 | 119.7% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 19.29 | 3.68% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 66.04 | 10.54% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.33 | 203.03% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | n/a | n/a | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.18 | 916.95% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 1.01 | 48.51% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | n/a | n/a | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 0.41 | 448.78% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 229.9 | 65.29% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | n/a | n/a | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 62.55 | 31.1% | 3 | Jan 16, 2019 |